Gene expression and identification of gene therapy targets in diabetic nephropathy

Jun Wada, Hirofumi Makino, Yashpal S. Kanwar

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

A number of novel genes that are upregulated in diabetic kidneys have been identified. Recently, transforming growth factor-β (TGF-β)-driven secreted proreins, i.e., connective tissue growth factor (CTGF) and gremlin, were identified. They are up-regulated in kidneys of diabetic animals and modulate the biology of mesangial cells. CTGF mediates TGF-β-induced matrix overproduction by the mesangial cells. Gremlin is a putative antagonist of bone morphogenetic protein-2 that blocks mesangial cell proliferation. Thus, gremlin may modulate the biology of mesangium by stimulating mesangial cell proliferation and in turn production of matrix. In addition, transcriptionally regulated kinases, serum glucocorticoid-regulated kinase and munc-13 have been identified. The former stimulates renal tubular Na+ transport and is involved in hyperfiltraion of diabetic kidneys by a Na+ transport feedback mechanism. Munc-13 has been shown to induce apoptosis in hyperglycemic state via diacylglyecrol-activated, PKC-independent signaling pathway. Another pathway relevant to diabetic nephropathy is polyol pathway, where glucose is reduced to sorbitol by aldose reductase. Recently, a renal-specific reductase of the aldo-keto reductase family was isolated. It is up-regulated in diabetic mice, and this could serve as a suitable target for gene therapy in renal complications of diabetes. Several mitochondrial genome-encoded genes, such as, cytochrome oxidase and NADH dehydrogenase, are up-regulated in diabetic kidneys. A novel nuclear-encoded mitochondrial gene, i.e., translocase inner mitochondrial membrane 44 (Tim44), is up-regulated in diabetic kidneys, and it may also serve as another target for molecular therapeutic intervention at the core storage energy sites, i.e., mitochondria. In this review, these novel differentially regulated genes that respond to hyperglycemic stress are described, and they may serve as possible targets for gene therapy in the treatment of diabetic nephropathy.

Original languageEnglish
JournalKidney International
Volume61
Issue numberSUPPL. 1
Publication statusPublished - 2002

Fingerprint

Diabetic Nephropathies
Genetic Therapy
Kidney
Gene Expression
Mesangial Cells
Connective Tissue Growth Factor
Transforming Growth Factors
Cell Proliferation
Genes
NADH Dehydrogenase
Aldehyde Reductase
Bone Morphogenetic Protein 2
Mitochondrial Genome
Mitochondrial Genes
Sorbitol
Mitochondrial Membranes
Electron Transport Complex IV
Diabetes Complications
Mitochondria
Oxidoreductases

Keywords

  • Aldo-keto reductase
  • Mitochondrial translocase

ASJC Scopus subject areas

  • Nephrology

Cite this

Gene expression and identification of gene therapy targets in diabetic nephropathy. / Wada, Jun; Makino, Hirofumi; Kanwar, Yashpal S.

In: Kidney International, Vol. 61, No. SUPPL. 1, 2002.

Research output: Contribution to journalArticle

@article{0007ebfaa1474600870180921ed14da4,
title = "Gene expression and identification of gene therapy targets in diabetic nephropathy",
abstract = "A number of novel genes that are upregulated in diabetic kidneys have been identified. Recently, transforming growth factor-β (TGF-β)-driven secreted proreins, i.e., connective tissue growth factor (CTGF) and gremlin, were identified. They are up-regulated in kidneys of diabetic animals and modulate the biology of mesangial cells. CTGF mediates TGF-β-induced matrix overproduction by the mesangial cells. Gremlin is a putative antagonist of bone morphogenetic protein-2 that blocks mesangial cell proliferation. Thus, gremlin may modulate the biology of mesangium by stimulating mesangial cell proliferation and in turn production of matrix. In addition, transcriptionally regulated kinases, serum glucocorticoid-regulated kinase and munc-13 have been identified. The former stimulates renal tubular Na+ transport and is involved in hyperfiltraion of diabetic kidneys by a Na+ transport feedback mechanism. Munc-13 has been shown to induce apoptosis in hyperglycemic state via diacylglyecrol-activated, PKC-independent signaling pathway. Another pathway relevant to diabetic nephropathy is polyol pathway, where glucose is reduced to sorbitol by aldose reductase. Recently, a renal-specific reductase of the aldo-keto reductase family was isolated. It is up-regulated in diabetic mice, and this could serve as a suitable target for gene therapy in renal complications of diabetes. Several mitochondrial genome-encoded genes, such as, cytochrome oxidase and NADH dehydrogenase, are up-regulated in diabetic kidneys. A novel nuclear-encoded mitochondrial gene, i.e., translocase inner mitochondrial membrane 44 (Tim44), is up-regulated in diabetic kidneys, and it may also serve as another target for molecular therapeutic intervention at the core storage energy sites, i.e., mitochondria. In this review, these novel differentially regulated genes that respond to hyperglycemic stress are described, and they may serve as possible targets for gene therapy in the treatment of diabetic nephropathy.",
keywords = "Aldo-keto reductase, Mitochondrial translocase",
author = "Jun Wada and Hirofumi Makino and Kanwar, {Yashpal S.}",
year = "2002",
language = "English",
volume = "61",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Gene expression and identification of gene therapy targets in diabetic nephropathy

AU - Wada, Jun

AU - Makino, Hirofumi

AU - Kanwar, Yashpal S.

PY - 2002

Y1 - 2002

N2 - A number of novel genes that are upregulated in diabetic kidneys have been identified. Recently, transforming growth factor-β (TGF-β)-driven secreted proreins, i.e., connective tissue growth factor (CTGF) and gremlin, were identified. They are up-regulated in kidneys of diabetic animals and modulate the biology of mesangial cells. CTGF mediates TGF-β-induced matrix overproduction by the mesangial cells. Gremlin is a putative antagonist of bone morphogenetic protein-2 that blocks mesangial cell proliferation. Thus, gremlin may modulate the biology of mesangium by stimulating mesangial cell proliferation and in turn production of matrix. In addition, transcriptionally regulated kinases, serum glucocorticoid-regulated kinase and munc-13 have been identified. The former stimulates renal tubular Na+ transport and is involved in hyperfiltraion of diabetic kidneys by a Na+ transport feedback mechanism. Munc-13 has been shown to induce apoptosis in hyperglycemic state via diacylglyecrol-activated, PKC-independent signaling pathway. Another pathway relevant to diabetic nephropathy is polyol pathway, where glucose is reduced to sorbitol by aldose reductase. Recently, a renal-specific reductase of the aldo-keto reductase family was isolated. It is up-regulated in diabetic mice, and this could serve as a suitable target for gene therapy in renal complications of diabetes. Several mitochondrial genome-encoded genes, such as, cytochrome oxidase and NADH dehydrogenase, are up-regulated in diabetic kidneys. A novel nuclear-encoded mitochondrial gene, i.e., translocase inner mitochondrial membrane 44 (Tim44), is up-regulated in diabetic kidneys, and it may also serve as another target for molecular therapeutic intervention at the core storage energy sites, i.e., mitochondria. In this review, these novel differentially regulated genes that respond to hyperglycemic stress are described, and they may serve as possible targets for gene therapy in the treatment of diabetic nephropathy.

AB - A number of novel genes that are upregulated in diabetic kidneys have been identified. Recently, transforming growth factor-β (TGF-β)-driven secreted proreins, i.e., connective tissue growth factor (CTGF) and gremlin, were identified. They are up-regulated in kidneys of diabetic animals and modulate the biology of mesangial cells. CTGF mediates TGF-β-induced matrix overproduction by the mesangial cells. Gremlin is a putative antagonist of bone morphogenetic protein-2 that blocks mesangial cell proliferation. Thus, gremlin may modulate the biology of mesangium by stimulating mesangial cell proliferation and in turn production of matrix. In addition, transcriptionally regulated kinases, serum glucocorticoid-regulated kinase and munc-13 have been identified. The former stimulates renal tubular Na+ transport and is involved in hyperfiltraion of diabetic kidneys by a Na+ transport feedback mechanism. Munc-13 has been shown to induce apoptosis in hyperglycemic state via diacylglyecrol-activated, PKC-independent signaling pathway. Another pathway relevant to diabetic nephropathy is polyol pathway, where glucose is reduced to sorbitol by aldose reductase. Recently, a renal-specific reductase of the aldo-keto reductase family was isolated. It is up-regulated in diabetic mice, and this could serve as a suitable target for gene therapy in renal complications of diabetes. Several mitochondrial genome-encoded genes, such as, cytochrome oxidase and NADH dehydrogenase, are up-regulated in diabetic kidneys. A novel nuclear-encoded mitochondrial gene, i.e., translocase inner mitochondrial membrane 44 (Tim44), is up-regulated in diabetic kidneys, and it may also serve as another target for molecular therapeutic intervention at the core storage energy sites, i.e., mitochondria. In this review, these novel differentially regulated genes that respond to hyperglycemic stress are described, and they may serve as possible targets for gene therapy in the treatment of diabetic nephropathy.

KW - Aldo-keto reductase

KW - Mitochondrial translocase

UR - http://www.scopus.com/inward/record.url?scp=0036177882&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036177882&partnerID=8YFLogxK

M3 - Article

C2 - 11841617

AN - SCOPUS:0036177882

VL - 61

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - SUPPL. 1

ER -